Introduction
Actin polymerization/depolymerization is a fundamental cellular process that controls cell shape, adhesion and migration. This dynamic cellular process is spatiotemporally regulated in normal cells but its dysregulation is often associated with cellular transformation and tumorogenesis (Pollard and Borisy, 2003; Rao and Li, 2004) . The WiscottAldrich Syndrome Protein (WASp) family proteins, which consist of WASp, N-WASP and WAVE/Scar 1, 2 and 3, are crucial components in the signaling network that regulates actin polymerization (Bompard and Caron, 2004; Stradal et al., 2004) . By interacting with actin and the Arp 2/3 complex, these proteins act as actin nucleation factors to promote actin polymerization. WASp family proteins are regulated by the small GTP-binding proteins Rac and Cdc42 (Bompard and Caron, 2004) . WASp and N-WASP, for example, contain a conserved Cdc42 binding domain. Association of GTP-bound Cdc42 to these proteins is a key step in their activation (Burns et al., 2004; Stradal et al., 2004) . WAVE proteins, however, are regulated by Rac through a different mechanism. WAVE proteins do not contain a Rac binding site and therefore do not directly bind to Rac. Instead, these proteins form a complex with Hspc 300, Abl interactor (Abi) proteins, Nck-associated protein 1 (Nap1) and specifically Rac-associated (Sra) protein (Eden et al., 2002; Gautreau et al., 2004; Innocenti et al., 2004; Kunda et al., 2003; Steffen et al., 2004) . Among these proteins, Abi plays a central role in holding the complex together, whereas Sra provides a binding site for active Rac (Gautreau et al., 2004; Innocenti et al., 2004; Steffen et al., 2004) . Recent studies suggest that the complex formation and subsequent translocation are crucial for WAVE activation Leng et al., 2005) . Still, how these cellular processes are regulated in cancer cells and whether the dysregulation of these cellular processes contributes to cellular transformation and tumorogenesis remain unclear.
Mammalian Abi proteins consist of three members, Abi1 (also known as e3b1), Abi2 and NESH (Biesova et al., 1997; Dai and Pendergast, 1995; Miyazaki et al., 2000; Shi et al., 1995; Wang et al., 1996; Ziemnicka-Kotula et al., 1998) . Among these, Abi1 and Abi2 were first identified as the binding partners of c-Abl as well as oncogenic v-Abl and BcrAbl tyrosine kinases (Dai and Pendergast, 1995; Shi et al., 1995) . Bcr-Abl tyrosine kinases are produced by a reciprocal t(9;22)(q34;q11) chromosomal translocation that fuses Hematopoietic cells isolated from patients with Bcr-Ablpositive leukemia exhibit multiple abnormalities of cytoskeletal and integrin function. These abnormalities are thought to play a role in the pathogenesis of leukemia; however, the molecular events leading to these abnormalities are not fully understood. We show here that the Abi1 pathway is required for Bcr-Abl to stimulate actin cytoskeleton remodeling, integrin clustering and cell adhesion. Expression of Bcr-Abl induces tyrosine phosphorylation of Abi1. This is accompanied by a subcellular translocation of Abi1/WAVE2 to a site adjacent to membrane, where an F-actin-enriched structure containing the adhesion molecules such as ␤1-integrin, paxillin and vinculin is assembled. Bcr-Abl-induced membrane translocation of Abi1/WAVE2 requires direct interaction between Abi1 and Bcr-Abl, but is independent of the phosphoinositide 3-kinase pathway. Formation of the F-actin-rich complex correlates with an increased cell adhesion to fibronectin. More importantly, disruption of the interaction between Bcr-Abl and Abi1 by mutations either in Bcr-Abl or Abi1 not only abolished tyrosine phosphorylation of Abi1 and membrane translocation of Abi1/WAVE2, but also inhibited Bcr-Abl-stimulated actin cytoskeleton remodeling, integrin clustering and cell adhesion to fibronectin. Together, these data define Abi1/WAVE2 as a downstream pathway that contributes to Bcr-Abl-induced abnormalities of cytoskeletal and integrin function. Abi1 in Bcr-Abl transformation varying amounts of the bcr gene on chromosome 22 with sequences upstream of the second exon of the c-abl gene on chromosome 9. Depending on the amount of bcr sequences fused, three different Bcr-Abl fusion proteins with molecular masses of 185 kDa (p185 Bcr-Abl ), 210 kDa (p210 Bcr-Abl ) and 230 kDa (p230 Bcr-Abl ) may be produced (Melo and Deininger, 2004) . Expression of Bcr-Abl is associated with more than 95% of human chronic myelogenous leukemia (CML) and a subset of acute lymphocytic leukemia cases (Melo and Deininger, 2004) . Hematopoietic cells isolated from CML patients exhibit multiple abnormalities of cytoskeletal function, such as increased motility, altered adhesion and decreased response to SDF-1␣ (Bazzoni et al., 1996; Gordon et al., 1987; Kramer et al., 1999; Salgia et al., 1997; Salgia et al., 1999; Verfaillie et al., 1992; Wertheim et al., 2003) . These abnormalities may play a crucial role in the progression of CML, as altered adhesion and increased motility may contribute to premature release of CML cells from bone marrow and accumulation of these cells in peripheral hematopoietic tissues such as blood and spleen. The abnormal cytoskeletal function observed in CML cells is caused by the Bcr-Abl oncoprotein, because expression of Bcr-Abl in hematopoietic cell lines is sufficient to induce these abnormalities (Kramer et al., 1999; McWhirter and Wang, 1997; Salgia et al., 1997; Wertheim et al., 2002; Wertheim et al., 2003) . Several lines of evidence suggest that Bcr-Abl deregulates ␤1-integrin function, which may, at least in part, be responsible for altered adhesion and increased motility of CML cells (Bhatia et al., 1996; Salesse and Verfaillie, 2002; Skorski et al., 1998; Verfaillie et al., 1992) . The ␤1-integrin is a subunit of integrin receptors found in hematopoietic cells that link the cytoskeleton to the extracellular matrix (Teixido et al., 1992; Verfaillie et al., 1992; Williams et al., 1991) . Although the expression of Bcr-Abl in CML cells did not alter the protein levels of membrane ␤1-integrin (Bazzoni et al., 1996; Verfaillie et al., 1992; Wertheim et al., 2002) , it induced abnormal interactions between ␤1-integrin and the actin cytoskeleton (Bhatia et al., 1999) . Bhatia et al. proposed that abnormal integrin-cytoskeletal interaction restricts the mobility of integrin receptors and results in defective integrin function in CML progenitor cells (Bhatia et al., 1999) . However, the precise mechanisms of Bcr-Abl-induced abnormal interaction of integrin and actin cytoskeleton remain largely unknown.
In previous studies we found that a mutant p185 Bcr-Abl with the deletion of the Src homology 3 (SH3) domain and Cterminal proline-rich sequences (p185
⌬SH3⌬C
) failed to induce a CML-like disease in a bone marrow transplant (BMT) mouse model (Dai et al., 2001 ). One pathological difference that distinguishes p185
BMT mice from wild-type p185
Bcr-Abl (p185 wt ) BMT mice is the lack of massive splenomegaly, a phenotype that is believed to result from the massive accumulation and retention of both mature and immature myeloid cells in the spleen. Notably, a proportion of p185 ⌬SH3⌬C BMT mice developed high peripheral white blood cell counts with normal spleen weight, suggesting that the p185 ⌬SH3⌬C was capable of stimulating cell proliferation and survival but failed to induce the accumulation and retention of myeloid cells in the spleen (Dai et al., 2001 ). These observations led us to hypothesize that p185 ⌬SH3⌬C may have a defect in stimulating abnormal cytoskeletal function. The SH3 domain and C-terminal proline-rich sequences are required for Bcr-Abl to bind to Abi1 and Abi2 (Dai et al., 2001; Dai and Pendergast, 1995; Shi et al., 1995) . Given that Abi signaling plays a key role in regulating actin polymerization, we sought to test whether this pathway is involved in Bcr-Ablinduced abnormalities of cytoskeletal function. Here we provide evidence that, through direct interaction with the SH3 domain and C-terminal proline-rich sequences of Bcr-Abl, Abi1 mediates Bcr-Abl-induced actin cytoskeleton remodeling and ␤1-integrin clustering. We also demonstrate that this pathway is required for Bcr-Abl to stimulate hematopoietic cell adhesion on fibronectin-coated surfaces.
Results

Differential regulation of Abi1 and Abi2 by Bcr-Abl in hematopoietic cells
We have previously shown that Abi proteins undergo ubiquitin-dependent degradation in hematopoietic cells transformed by Bcr-Abl (Dai et al., 1998) . Although the antibody used in the previous studies was raised against Abi2 and was immunoreactive preferentially to Abi2, it crossreacted, albeit weakly, with in vitro synthesized Abi1 (supplementary material Fig. S1A ). Without a specific antibody to Abi1, our earlier studies were unable to distinguish if the Bcr-Abl-induced degradation of Abi is specific for Abi2 or if it is common to both Abi1 and Abi2 (Dai et al., 1998) . To address this question, we made use of an antibody raised against a peptide with sequences unique to Abi1 (Courtney et al., 2000) , This antibody specifically recognizes Abi1 with no detectable cross-reactivity to Abi2 (supplementary material Fig. S1A ). Using this antibody, we examined the expression of Abi1 in murine pro-B cell line Ba/F3 and myeloid cell line 32D, as well as their derivatives transformed by p185 wt . Abi1 was readily detected in control Ba/F3 and 32D cells transduced with an empty retroviral vector (Fig. 1A) . There was no significant decrease in Abi1 protein level in Ba/F3 and 32D cells transformed by Bcr-Abl, as compared with the control cells (Fig. 1A) . This is in contrast to our previous studies using Abi2 antibody, which detected immunoreactive proteins only in control Ba/F3 and 32D cells but not in those transformed by p185 wt (Dai et al., 1998 ) (see also supplementary material Fig. S1B ). Thus, the result suggests that Abi2, but not Abi1, is downregulated by Bcr-Abl in hematopoietic cells.
We noticed that the Bcr-Abl transformation induced additional bands with slower mobility on western blots that were recognized by Abi1 antibody (Fig. 1A , middle panel, compare lanes 2 and 4 with lanes 1 and 3). The slower mobility species represent tyrosine-phosphorylated Abi1 as these proteins can be immunoprecipitated by Abi1 antibody and recognized either by Abi1 antibody or the antibody specific to phosphotyrosine proteins on western blots (Fig. 1B, lanes 2 and  4) . A kinase-deficient Bcr-Abl mutant (p185 K671R ) was unable to induce Abi1 tyrosine phosphorylation (Fig. 1B, lane 3) , suggesting that the tyrosine kinase activity of Bcr-Abl is required for induction of Abi1 tyrosine phosphorylation. In support of this notion, the tyrosine phosphorylation of Abi1 was completely inhibited by imatinib mesylate, a compound that specifically blocks Bcr-Abl kinase activity (Fig. 1B, 7 cells were immunoprecipitated (IP) with anti-Abi1 antibody, followed by western blot analysis using anti-phosphotyrosine (␣-pTyr) antibody (upper panel). The blots were then stripped and reprobed with anti-Abi1 antibody (lower panel). The relative molecular mass (M r ) is indicated and presented as kilodaltons (kd). wt were lysed and fractionated to separate the cytosol (C) and plasma membrane (M). The equal amounts of total lysate (I, input), cytosol, and membrane fractions were separated on SDS-PAGE and analyzed by western blot using antibodies specific to Abi1 and WAVE2, as indicated. To monitor the quality of the fractionation, the blot was also probed with the antibodies to the ␤-subunit of IL-3 receptor and ␣-tubulin, the proteins known to be in membrane and cytosol, respectively. Abi1 in Bcr-Abl transformation p185 wt (Fig. 2B, left panel) , suggesting that these proteins form a complex in vivo and that the complex formation was not affected by Bcr-Abl transformation. Consistent with this notion, the reciprocal immunoprecipitation with WAVE2 antibody demonstrated that both tyrosine-phosphorylated and non-phosphorylated forms of Abi1 were capable of binding to WAVE2 (Fig. 2B , lane 5). Based on these results, we conclude that it is unlikely that the signaling from Bcr-Abl to Abi1 plays a major role in regulation of Abi1/WAVE2 complex formation in Ba/F3 cells.
Next, we tested whether Bcr-Abl signaling plays a role in regulating subcellular localization of Abi1 and WAVE2. To this end, retroviruses expressing either a green fluorescent protein (GFP)-tagged Abi1 or WAVE2 were generated and introduced into Ba/F3 cells as well as the Ba/F3 cells expressing p185 wt or p185 K671R . The subcellular distribution of GFP-Abi1 and GFP-WAVE2 were then examined by two-photon confocal microscopy. Both GFP-Abi1 and GFP-WAVE2 exhibited a diffuse cytoplasmic distribution in control Ba/F3 cells (Fig. 2C, a, d) . By contrast, a polarized cytoplasmic localization of GFP-Abi1 and GFP-WAVE2 was observed in Ba/F3 cells transformed by p185 wt (Fig. 2C ,b,e). In particular, Abi1 and WAVE2 were found concentrated in a spot adjacent to the membrane. This distribution pattern of Abi1 is not an artifact caused by overexpression or by GFP fusion, as the same pattern was observed for endogenous Abi1 in p185 wt -transformed cells by indirect immunofluorescence staining (see Fig. 3 ). The fact that a kinase-deficient p185 K671R was unable to induce such a pattern (Fig. 2C ,c,f) further supports that the polarized cytoplasmic localization of GFP-Abi1 and WAVE2 was indeed induced by Bcr-Abl tyrosine kinase.
To determine whether Abi1 and WAVE2 were associated with plasma membrane in Bcr-Abl-transformed cells, a subcellular fractionation experiment was performed. As shown in Fig. 2D , Abi1 and WAVE2 were found in both cytosol and membrane fractions in parental Ba/F3 cells. However, we observed an increase in membrane-associated Abi1 and WAVE2 in cells transformed by p185
wt Bcr-Abl (Fig. 2D , compare lane 6 with lane 5). This finding is consistent with the observation that, upon Bcr-Abl transformation, most Abi1 and WAVE2 were relocated to a site adjacent to the membrane (Fig.  2C ). Together, our results indicate that Bcr-Abl transformation induces a translocation of Abi1/WAVE2 to plasma membrane.
Abi1, Bcr-Abl and WAVE2 colocalize with an F-actinenriched structure in Bcr-Abl-transformed hematopoietic cells Given that the Abi1/WAVE2 pathway plays a central role in regulating actin polymerization , we asked whether the membrane translocation of Abi1/WAVE2 is associated with Bcr-Abl-induced abnormal actin cytoskeleton remodeling. Consistent with previous reports (McWhirter and Wang, 1997; Salgia et al., 1997; Skourides et al., 1999) , expression of p185 wt in Ba/F3 cells induced a profound actin cytoskeleton remodeling. A spot intensively stained by TRITCconjugated phalloidin, indicative of an aggregate of filamentous actin (F-actin), was observed in p185 (Fig. 3a-c) and Bcr-Abl (Fig. 3d-f ) colocalize with this F-actin-enriched structure. To determine whether WAVE2 also colocalizes with this abnormal structure, the p185 wt -transformed Ba/F3 cells were transduced with the retrovirus expressing GFP-WAVE2 and cells were counterstained by TRITC-conjugated phalloidin. The GFP-WAVE2 and F-actin were visualized by two-photon confocal microscopy. As shown in Fig. 3 , WAVE2 ( Fig. 3g-i ) also colocalizes with the F-actin-enriched structure.
␤1-integrin, paxillin and vinculin are clustered and associated with F-actin-enriched structures in Bcr-Abltransformed cells Actin cytoskeleton organization plays a key role in regulation of integrin distribution and function (Schwartz et al., 1995) . To determine whether the abnormal F-actin-enriched structures induced by p185 wt affects membrane distribution of integrin, Fig. 3 . Colocalization of Abi1, Bcr-Abl and WAVE2 with an abnormal F-actin-rich structure. Ba/F3 cells expressing p185 wt were probed with anti-Abi1 (a-c) and anti-Abl (d-f) antibodies, respectively. This was followed by staining with FITC-conjugated secondary antibody. Cells were then counterstained with TRITCconjugated phalloidin and DAPI to visualize F-actin and nuclei, respectively. In g-i, the Ba/F3 cells expressing p185 wt were transduced with retrovirus expressing GFP-WAVE2 and counterstained by TRITC-conjugated phalloidin and DAPI. Subcellular distribution of Abi1 (a, green), Bcr-Abl (d, green), GFP-WAVE2 (g, green) and F-actin structures (b,e,h, red) were visualized by two-photon confocal microscopy, as indicated by arrowheads. The colocalization of these proteins with abnormal F-actin structure is shown by merged images (c,f,i). Bar, 10 m.
we stained control Ba/F3 cells and the Ba/F3 cells expressing either p185
wt or p185 K671R with FITC-conjugated antibody specific for ␤1-integrin, a common subunit of integrin receptors found in hematopoietic cells (Teixido et al., 1992; Verfaillie et al., 1992) . As shown in Fig. 4A (left panel) , the control Ba/F3 cells displayed even membrane distribution of ␤1-integrin. By contrast, ␤1-integrin in Ba/F3 cells transformed by p185 wt was clustered (Fig. 4A, middle panel) . The ␤1-integrin clustering was Bcr-Abl tyrosine kinase dependent, as the kinase-deficient p185 K671R failed to induce
Journal of Cell Science 120 (8) such clustering (Fig. 4A , right panel). To determine whether the clustered ␤1-integrin is associated with abnormal actinenriched structure, cells were counterstained with TRITCconjugated phalloidin following the immunofluorescence staining with anti-␤1-integrin antibody. As shown in Fig. 4B ,ac, the clustered ␤1-integrin was found to colocalize with the abnormal actin-enriched structures. Furthermore, paxillin (Fig.  4B ,d-f) and vinculin (Fig. 4B,g-i) , the adhesion proteins known to link integrin to the cytoskeleton (Burridge et al., 1988) , were also found in association with the F-actin-enriched structures in p185
wt -expressing cells. The association of the F-actinenriched structures with adhesion proteins and ␤1-integrin appeared to be specific, as ␣-tubulin, a cytoplasmic protein, was not found to colocalize with this abnormal structural complex (Fig. 4B,j-l) . Together, these results suggest that p185 wt -induced F-actin-enriched structures interacted with ␤1-integrin, possibly through adhesion-associated molecules such as paxillin and vinculin.
PI3K pathway is not required for Bcr-Abl-induced Abi1 translocation and F-actin remodeling Innocenti et al. recently reported that Abi1 interacts with the p85 subunit of phosphoinositide 3-kinase (PI3K) to form a multimolecular complex localized in membrane ruffle (Innocenti et al., 2003) . The formation of this multimolecular complex is crucial for activation of Rac and Rac-dependent actin remodeling (Innocenti et al., 2003) . To test whether the PI3K pathway is also involved in Bcr-Abl-induced Abi1 translocation and F-actin remodeling, three approaches were explored. First, immunoprecipitation followed by western blotting was performed to determine whether Abi1 forms a complex with the p85 subunit of PI3K. As shown in Fig. 5A (left panel, lanes 3 and 4), under the condition in which WAVE2 was coimmunoprecipitated by Abi1 antibody, we were unable to detect p85 in anti-Abi1 immunoprecipitates from Ba/F3 cells and p185 wt -transformed cells. Similarly, the antip85 antibodies failed to coimmunoprecipitate Abi1 from Ba/F3 cells and p185 wt -transformed cells (Fig. 5A, right panel) . Second, because the phosphorylation of tyrosine 407 in Abi1 is required for its interaction with p85 as well as for growth factor-stimulated actin remodeling (Innocenti et al., 2003) , we asked whether the mutation of this tyrosine affects the Bcr-Ablinduced Abi1 translocation and F-actin remodeling. A substitution of tyrosine 407 with phenylalanine in Abi1 (Abi1 (Fig. 5B and supplementary material Fig. S2B) . Further, the expression of Abi1 Y407F had no effects on p185 wt -induced F-actin remodeling (supplementary material Fig.  S2B,h ). Together, these results suggest that the tyrosine 407 of Abi1 is not a major phosphorylation site required for Bcr-Ablinduced Abi1 translocation and F-actin remodeling. Finally, we made use of a specific PI3K inhibitor, LY294002, to test whether the pharmacological inhibition of PI3K has any effect on Bcr-Abl-induced Abi1 membrane translocation and F-actin remodeling. The p185 wt -transformed Ba/F3 cells were transduced with retrovirus expressing GFP-Abi1 and treated were starved, fixed, permeabilized and probed with FITC-conjugated antibodies against ␤1-integrin, paxillin, tubulin and vinculin (green), as indicated. The cells were then counterstained with TRITCconjugated phalloidin (red) and DAPI (blue) to visualize F-actin and nuclei, respectively. Images were captured by two-photon confocal microscopy and the colocalization of integrin, paxillin and vinculin with abnormal actin-enriched structure is shown in merged images, as indicated by arrowheads. Bar, 10 m. Abi1 in Bcr-Abl transformation with either LY294002 or the Bcr-Abl inhibitor imatinib. In contrast to imatinib, which effectively inhibited the Bcr-Ablinduced Abi1 translocation (Fig. 5C , middle panel), LY294002 had no effects on the membrane translocation of GFP-Abi1 (Fig. 5C, right panel) . Similarly, the formation of F-actinenriched structures in p185 wt -transformed Ba/F3 cells was inhibited by imatinib (supplementary material Fig. S2A,c) , but not LY294002 (supplementary material Fig. S2A,d) . Collectively, the results from these studies support that BcrAbl induces Abi1 translocation and F-actin remodeling independently of the PI3K pathway.
Abi1 pathway is required for Bcr-Abl-induced actin cytoskeleton remodeling and integrin clustering To determine whether the Abi1 pathway is required for BcrAbl-induced abnormal actin remodeling and integrin clustering, we made use of p185
⌬SH3⌬C
, a mutant Bcr-Abl with the deletion of the SH3 domain and C-terminal proline-rich sequences (supplementary material Fig. S3A ). In previous studies we and others have shown that the SH3 domain and Cterminal proline-rich sequences are required for Bcr-Abl to bind to Abi1 and Abi2 (Dai et al., 2001; Shi et al., 1995) . Deletion of these sequences did not affect tyrosine kinase activity of p185 ⌬SH3⌬C (Dai et al., 2001 ), but completely abolished its ability to bind to Abi1 and to induce Abi1 tyrosine phosphorylation (supplementary material Fig. S3B ). Deletion of these sequences also caused the inability of p185 ⌬SH3⌬C to induce membrane translocation of Abi1 (Fig. 6A,b) and WAVE2 (Fig. 6A,d ) in Ba/F3 cells. Together, these results indicate that p185 ⌬SH3⌬C is defective in signaling to the Abi1 pathway. Correlated with this defect, p185
⌬SH3⌬C failed to induce abnormal F-actin-rich structures (Fig. 6B,h ) and ␤1-integrin clustering (Fig. 6B,f) when expressed in Ba/F3 cells. These results are consistent with a role for the Abi1 pathway in Bcr-Abl-induced abnormal actin remodeling and integrin clustering.
In addition to Abi1, the SH3 domain and C-terminal prolinerich sequences of Bcr-Abl also interact with other signaling molecules. It is therefore possible that the failure of p185 ⌬SH3⌬C to induce actin-enriched structures is because of its inability to activate these pathways, rather than the Abi1 pathway. To directly test the role of the Abi1 pathway in BcrAbl-induced abnormal actin remodeling, we generated Abi1 PPLL , a mutant Abi1 in which the proline residues 180 and 434 in the PXXP motif and the SH3 domain, respectively, are replaced by leucine (Fig. 7A) . Previous studies suggest that proline 180 is likely to be involved in the interaction with the Abl SH3 domain (Dai and Pendergast, 1995; Ren et al., 1994) , whereas proline 434 is highly conserved among a diverse set of SH3 domains and is thought to be crucial for binding to the Abl C-terminal PXXP motif (Dai and Pendergast, 1995; Musacchio et al., 1992 ; Ren et al., 1994; Van Etten et al., 1995) . The mutations of these proline residues resulted in the inability of Abi1 PPLL to bind to BcrAbl (Fig. 7B ) and to be tyrosine-phosphorylated when expressed in p185 wt -transformed cells (Fig. 7C) . The mutant protein, however, retains the ability to interact with WAVE2 (supplementary material Fig. S4A ) and Hem1 (supplementary material Fig. S4B ), a member of Nap1 family proteins specifically expressed in hematopoietic cells (Weiner et al., 2006) . We therefore predicted that this mutant Abi1, when
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overexpressed in p185 wt -transformed cells, may serve as a dominant-negative molecule to interfere with the signal transduction from Bcr-Abl to endogenous Abi1. To test this, retroviruses expressing GFP-tagged wild-type Abi1 and Abi1 PPLL were generated and introduced into Ba/F3 cells expressing p185 wt . The cells were then stained with TRITCconjugated phalloidin and subjected to two-photon confocal microscopy analysis. As shown in Fig. 7D , whereas the wildtype Abi1 was found to colocalize with the F-actin-enriched wt (e,g) or p185
⌬SH3⌬C (f,h) were fixed and incubated with FITC-conjugated monoclonal antibody specific for ␤1-integrin (e,f). The cells were also stained with TRITCconjugated phalloidin to visualize F-actin (g,h). The nuclei of the cells were stained by DAPI (blue) and the arrowheads indicate the subcellular localization of GFP-Abi1 (a), WAVE2 (c), clustering ␤1-integrin (e), as well as abnormal actin-enriched structures (g) in p185
wt -transformed cells. Bar, 10 m. (Fig. 7D , compare panels cf), indicating that the expression of Abi1 PPLL inhibited BcrAbl-induced actin cytoskeleton remodeling. This finding, together with the finding that p185 ⌬SH3⌬C failed to induce the F-actin-enriched structure (Fig. 6 ), strongly supports a role for Abi1 in Bcr-Abl-induced actin cytoskeleton reorganization.
Blockade of the Abi1 pathway or ␤1-integrin function impairs Bcr-Abl-stimulated hematopoietic cell adhesion on fibronectin-coated surfaces Actin cytoskeleton structure and integrin function are pivotal for control of cell adhesion (Hynes, 2002; Martin et al., 2002; Schwartz and Ginsberg, 2002) . The finding that the Abi1 pathway is required for Bcr-Abl to induce abnormal actin remodeling and integrin clustering raises the question as to whether this pathway is responsible for abnormal adhesion of Bcr-Abl-positive leukemic cells to fibronectin, a phenotype thought to play a role in the pathogenesis of CML (Bazzoni et al., 1996; Gordon et al., 1987; Hemmeryckx et al., 2001; Salesse and Verfaillie, 2002; Wertheim et al., 2003) . To address this question, we examined the adhesion of p185 wt -transformed Ba/F3 cells to fibronectin-coated surfaces and compared it with those of control Ba/F3 cells as well as the Ba/F3 cells expressing p185
⌬SH3⌬C
, the mutant Bcr-Abl defective in signaling to Abi1. Consistent with the previous reports (Bazzoni et al., 1996; Wertheim et al., 2003) , expression of p185 wt in Ba/F3 cells increased cell adhesion to fibronectincoated surfaces threefold compared with parental cells (Fig.  8A) . However, the ability of Bcr-Abl to stimulate Ba/F3 cell adhesion was greatly reduced by deletion of the SH3 and Cterminal proline-rich sequences (Fig. 8A, left panel) , suggesting that the Abi1 pathway is required for Bcr-Abl to stimulate cell adhesion to fibronectin. This is further supported by study of Abi1 PPLL , a mutant Abi1 defective in binding to Bcr-Abl (Fig. 7B) . We have shown that expression of Abi1 PPLL inhibited Bcr-Abl-induced actin cytoskeleton remodeling (Fig.  7C) . Correlating with its inhibitory effect on actin cytoskeleton remodeling, expression of Abi1 PPLL in p185 wt -transformed Ba/F3 cells resulted in a remarkable decrease in cell adhesion to fibronectin, as compared with parental p185 wt -transformed cells (Fig. 8A, right panel) .
It is unlikely that the increased cell adhesion to fibronectin in p185 wt -transformed cells is caused by an elevation of integrin expression, as no significant increase in ␤1-integrin protein level was observed among BaF3 cells and the Ba/F3 derivatives expressing the wild-type and mutant forms of BcrAbl (supplementary material Fig. S5 ). However, the increased adhesion of p185 wt -transformed cells to fibronectin-coated surfaces correlated with the induction of the F-actin-enriched structures. This is demonstrated by analysis of the F-actinenriched structures in p185 wt -transformed Ba/F3 cells grown in fibronectin-coated plates. The cells adhered to fibronectincoated surfaces and those that remained in suspension were collected separately and analyzed for F-actin-enriched structures by fluorescence microscopy. As shown in Fig. 8B , more than 86% of adherent cells displayed abnormal F-actinenriched structures. By contrast, only 27% of suspension cells were found to have such structures. The enrichment of the Factin-rich structures in adherent cells is not because of the stimulation by surface-bound fibronectin, as the addition of fibronectin into culture medium did not increase the formation of the F-actin-enriched structures in suspension cells (Fig. 8B) . Rather, it is more likely that Bcr-Abl-induced F-actin-enriched structures enable cells to adhere to fibronectin-coated surfaces, possibly by promoting integrin clustering. In support of this notion, ␤1-integrin was found clustered and colocalized with F-actin-enriched structures in adherent Ba/F3 cells transformed by p185 wt , but not p185 ⌬SH3⌬C (supplementary material Fig.  S6 ). Furthermore, Bcr-Abl-stimulated cell adhesion to fibronectin is ␤1-integrin-dependent and is abrogated completely by the treatment with Ha2/5 (Fig. 8C) , a specific ␤1-integrin antibody capable of blocking ␤1-integrin-mediated cell adhesion.
Discussion
Previous work has shown that deletion of the SH3 domain and C-terminal proline-rich sequences of p185
Bcr-Abl impaired its ability to induce leukemogenesis (Dai et al., 2001) . The mechanism involved, however, was not clear. In this study, we demonstrate that the SH3 domain and C-terminal proline-rich sequences are required for Bcr-Abl to induce the tyrosine phosphorylation of Abi1 and membrane translocation of Abi1/WAVE2. Deletion of these sequences not only abolished the tyrosine phosphorylation of Abi1 and membrane translocation of Abi1/WAVE2, but also abrogated the ability of Bcr-Abl to induce actin cytoskeleton remodeling and ␤1-integrin clustering. Mutant Bcr-Abl with the deletion of these sequences is also deficient in stimulating hematopoietic cell adhesion to fibronectin. Furthermore, expression of a mutant Abi1 defective in binding to the SH3 domain and C-terminal proline-rich sequences of Bcr-Abl inhibited abnormal actin cytoskeleton remodeling and Bcr-Abl-stimulated cell adhesion. Together, these findings place Abi1 signaling as an immediate downstream pathway that links p185
Bcr-Abl to abnormal cytoskeletal function. These results may provide a mechanistic explanation of why p185 ⌬SH3⌬C failed to induce CML-like disease in BMT mice (Dai et al., 2001) .
Integrin receptors link the force-generating actin cytoskeleton to extracellular matrix and, therefore, play a central role in the control of cell adhesion and motility. The integrin function is regulated by not only extracellular matrix, but also actin cytoskeleton and other membrane or intracellular signaling molecules (Hynes, 2002; Martin et al., 2002; Schwartz and Ginsberg, 2002) . In Bcr-Abl-positive leukemic cells, integrin function is abnormal and this abnormality is believed to be caused by abnormal integrin-cytoskeletal interaction (Bhatia et al., 1999) . The pathways that link BcrAbl to abnormal integrin-cytoskeletal interaction, however, remain to be defined. We found that ␤1-integrin was clustered and was associated with an F-actin-enriched structure in p185 wt -transformed Ba/F3 cells. The constitutive clustering of ␤1-integrin was independent of extracellular stimulation Journal of Cell Science 120 (8) because it was found in the resting p185 wt -transformed cells grown in suspension. The interaction of ␤1-integrin with the abnormal actin-enriched structure, which was induced by p185
Bcr-Abl through the Abi1 pathway, is probably a causative event for ␤1-integrin clustering. This is supported by the finding that the blockade of the signaling from Bcr-Abl to Abi1 abrogated not only abnormal actin cytoskeleton remodeling but also integrin clustering. Thus, our studies show, for the first time, that the Abi1 pathway is required for Bcr-Abl to induce abnormal integrin-cytoskeletal interaction. Notably, the Factin-enriched structures observed in p185 wt -transformed cell lines are also present in hematopoietic cells isolated from a CML patient (Bhatia et al., 1999) (Y.L. and Z.D., unpublished data) , suggesting that a similar mechanism may also be utilized by CML cells to deregulate integrin function and cell adhesion.
In addition to abnormal cell adhesion, the Abi1 pathway may also contribute to other cellular processes crucial for leukemic cell homing, such as cell migration and invasion. This is supported by our previous observation that deletion of the SH3 domain and C-terminal proline-rich sequences in Bcr-Abl not only abrogated its signaling to Abi1, but also inhibited its ability to induce spontaneous migration of Ba/F3 cells on fibronectin-coated surfaces (Dai et al., 2001) . Consistent with this observation, expression of Abi1 PPLL in p185 wt -transformed cells not only inhibited Bcr-Abl-induced abnormal actin remodeling and cell adhesion, but also impaired the spontaneous cell migration on fibronectin-coated surfaces (supplementary material Fig. S7 ). Further, ablation of Abi1 in p185 wt -transformed Ba/F3 cells by short hairpin RNA not only inhibited Bcr-Abl-stimulated actin cytoskeleton remodeling and cell adhesion, but also impaired Bcr-Abl-induced spontaneous cell migration and leukemogenesis (W.Y. and Z.D., unpublished data). Taken together, these results provide the strong evidence that the Abi1 pathway plays an important role in Bcr-Abl-induced leukemogenesis.
In a recent report, Leng et al. demonstrated that, when stimulated, c-Abl tyrosine kinase induced the tyrosine phosphorylation of Abi1 and promoted Abi1/WAVE2 membrane translocation (Leng et al., 2005) . In this study, we have shown that p185
Bcr-Abl , a constitutively active tyrosine kinase, stimulated Abi1 tyrosine phosphorylation and membrane translocation of the Abi1/WAVE2 complex. These studies highlight membrane translocation of Abi1/WAVE2 as a crucial regulatory step for WAVE activation and actin cytoskeleton reorganization. Using a melanoma cell line B16F1, Leng et al. also reported that WAVE2 was phosphorylated on tyrosine 150 and that the complex assembly of Abi1 and WAVE2 was enhanced when c-Abl was activated by platelet-derived growth factor (PDGF) stimulation (Leng et al., 2005) . In studies described here, we did not observe an increase in Abi1/WAVE2 complex assembly in p185 wt -transformed Ba/F3 cells (Fig. 2B) . In fact, we found that even in resting Ba/F3 cells, most of Abi1 and WAVE2 present as a complex and can be easily coimmunoprecipitated with each other (L.D. and Z.D., unpublished data). This observation is in line with those described by Gautreau et al. (Gautreau et al., 2004) and Innocenti et al. , who demonstrated that Abi, Nap, Sra and WAVE2 were only present as a complex in HeLa cells and that stimulation of cells with epidermal growth factor (EGF) did not affect the complex formation. Although the discrepancy between our observations and those reported by Leng et al. may be explained by differences in experimental systems, our data and those of Leng et al. raise the possibility that c-Abl and Bcr-Abl may regulate complex formation of Abi1/WAVE2 differently.
The mechanism by which Bcr-Abl induces membrane translocation of Abi1 in hematopoietic cells differs from those utilized by fibroblasts and adherent tumor cells such as HeLa cells and melanoma cells B16F1, in which Abi1 was found to localize to the membrane ruffle and the tip of the lamellipodia (Stradal et al., 2001; Innocenti et al., 2004; Leng et al., 2005) . The PI3K pathway, for example, is required for PDGFstimulated membrane translocation of Abi1 in fibroblasts (Innocenti et al., 2003) , but is dispensable for Bcr-Abl-induced Abi1 translocation in hematopoietic cells. Abi1 PPLL , a mutant Abi1 deficient in binding to Bcr-Abl, failed to translocate to membrane in p185 wt -transformed Ba/F3 cells. However, this mutant Abi1 displayed the same membrane-associated distribution as the wild-type Abi1 in adherent human kidneyderived 293 cells (X.S. and Z.D., unpublished data). Although the tyrosine phosphorylation of Abi1 appears to be crucial for its membrane translocation in both fibroblasts (Innocenti et al., 2003; Leng et al., 2005) and Bcr-Abl-transformed hematopoietic cells, the mechanism involved differs too. The phosphorylation of tyrosine 407 has been shown to be crucial for membrane translocation of Abi1 in fibroblasts, as it provides an anchorage site for PI3K (Innocenti et al., 2003) . This tyrosine, however, is not required for Bcr-Abl-induced Abi1 translocation in hematopoietic cells (Fig. 5) . It is possible that Bcr-Abl may induce the phosphorylation of other tyrosine residue(s) in Abi1, which may provide an anchorage site for proteins yet to be identified or, alternatively, which may modify the actin polymerization-promoting activity of the Abi1/WAVE2 complex. Further investigation is necessary to map these tyrosine residue(s) and to define the role of tyrosine phosphorylation of Abi1 in the regulation of membrane translocation.
Materials and Methods
Cell lines and reagents
Ba/F3 and 32D cells were grown in RPMI containing 10% fetal bovine serum (FBS) and 15% WEHI3-conditioned medium as a source of IL-3. The Ba/F3 and 32D cell lines expressing wild type and the mutant forms of p185
Bcr-Abl were generated by retroviral transduction, as described previously (Dai et al., 2001 ). Retroviral packaging cell line Bosc 23, kindly provided by W.S. Pear (University of Pennsylvania), was grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS. The preparation of rabbit polyclonal antibodies against Abi1 and Abi2 has been described previously (Courtney et al., 2000; Dai et al., 1998) . The antibodies against WAVE2, the p85 subunit of PI3K, and phosphotyrosinecontaining proteins were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The monoclonal antibodies for Abl and ␤1-integrin (Ha2/5 and 9EG7) were obtained from BD Pharmingen (San Diego, CA). The other antibodies used were: monoclonal anti-␤-actin (Sigma), FITC-conjugated monoclonal anti-␤1-integrin (Chemicon International), anti-paxillin (BD Transduction Laboratories), and antivinculin (Sigma). The Abl tyrosine kinase inhibitor, imatinib mesylate (Gleevec), was kindly provided by J. DeGregori (University of Colorado Health Sciences Center). The protease inhibitor cocktail was purchased from Sigma.
Retroviral constructs
The full-length cDNA encoding enhanced GFP (eGFP) was generated by polymerase chain reaction (PCR) using pEGFP-C plasmid as template. The resultant cDNA fragment, which contains a 5Ј BamHI site and 3Ј BglII/XhoI/EcoRI sites, was digested by BamHI/EcoRI and subcloned into murine stem cell virus (MSCV) at BglII and EcoRI sites. The resultant plasmid, MSCV-GFP, was used to construct the retroviral vectors expressing wild-type and mutant forms of GFP-Abi1 and GFP-WAVE2 fusion proteins. Briefly, cDNAs encoding Abi1 and WAVE2 were generated by PCR, and subcloned in-frame into MSCV-GFP at BglII/EcoRI sites. The cDNAs encoding Abi1
PPLL were generated using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) and subcloned into MSCV-GFP at BglII/EcoRI sites, as specified by the manufacturer. The mutations were confirmed by sequencing analysis.
Fluorescence microscopy
Cultured Ba/F3 cell lines were starved for 4 hours in RPMI containing 0.5% bovine serum albumin (BSA) before fixation and staining. The starved cells were then fixed in 3.7% formaldehyde in PBS for 10 minutes, permeabilized in 0.2% Triton X-100/PBS for 5 minutes, and stained with 50 g/ml TRITC-conjugated phalloidin (Sigma) in PBS. After washing extensively with PBS and a brief staining with DAPI (Sigma) to visualize nuclei, 5-10ϫ10 3 cells were loaded per slide by cytospin and mounted with Vectashield mounting medium (Vector, Burlingame, CA). Images were captured and analyzed using a Zeiss two-photon laser scanning confocal microscope with LSM 5 Image software. For indirect immunofluorescence staining of Abi1 and Bcr-Abl, cells stained with TRITC-phalloidin as above were blocked with 2% BSA in PBS for 1 hour, and incubated with appropriate antibodies diluted in 1% BSA/PBS for 2 hours. After extensive washing with PBS, cells were incubated with Alexa-conjugated secondary antibodies (1:500; Molecular Probes, Eugene, OR) for 1 hour, washed again with PBS, and mounted on slides, as described above. The immunofluorescence staining for ␤1-intergrin was performed in both suspension cells and the cells adherent to fibronectin-coated surfaces as described above, except that for suspension cells, they were fixed in 3.7% formaldehyde in PBS for 10 minutes without permeabilization.
Biochemical assays
Subcellular fractionation was performed as described (Wartmann et al., 1997) with modifications. Briefly, cells were disrupted by passing through a 27G 1/2 needle in hypotonic buffer (25 mM HEPES, pH 7.5; 2 mM EDTA, 2 mM NaVO 4 , 5 mM NaF, and 1% protease inhibitor cocktail), and centrifuged for 15 minutes at 600 g to separate the nuclei and cytosol/membrane fractions. The supernatant was then centrifuged for 30 minutes at 100,000 g to yield the cytosol (S100) fraction and the membrane pellet (P100). For coimmunoprecipitation analysis, control Ba/F3 cells and the Ba/F3 cells expressing wild-type and mutant forms of p185
Bcr-Abl were lysed in lysis buffer (20 mM HEPES, pH 7.2; 150 mM NaCl, 1% Triton X-100, and 10% glycerol) and incubated with appropriate antibodies bound to Sepharose beads. The immunoprecipitates were separated on SDS-PAGE, transferred to nitrocellulose and immunoblotted with appropriate antibodies. ) 15% WEHI3-conditioned medium at a density of 1ϫ10 5 cells/ml. The cells were plated in six-well plates (2.5 ml/well) coated with fibronectin (BD Biosciences, Bedford, MA) and incubated at 37°C/5%CO 2 for 16 hours. Nonadherent cells were removed and adherent cells were washed three times with 1 ml pre-warmed RPMI medium. The adherent cells were then trypsinized and collected. Both nonadherent and adherent cells were counted to determine the percentage of adherent cells. For treatment of p185 wt -transformed cells with blocking antibody, either Ha2/5 anti-integrin antibody or control hamster IgM was added to cells (4 g/2.5ϫ10 5 cells) in fibronectin-coated six-well plates. The cells were incubated at 37°C/5%CO 2 for 16 hours and cell adhesion was determined as described above.
Cell adhesion assay
